Show channels:
All channels
Bladder cancer
Brain and spinal
Breast cancer
Cervical
Colon & rectal
Dermatological
General Information
Gynecological
Head and Neck
Kidney/adrenal
Liver
Lung
Lymphoma
Multiple Myeloma
Myelodysplastic syndromes
Myeloproliferative disorders
Pancreas
Pediatric
Prostate
Sarcoma
Stomach
Testicular
Thyroid
Upper aerodigestive
Found 16137 articles
Carboxylesterase 1 is a core metabolic vulnerability of platinum-resistant high-grade serous ovarian carcinoma
Metabolic stress induced shift from glycolysis to OXPHOS and promoted platinum resistance in EOC cells.
»
07/24/26
Investigation of the significance and role of androgen receptor expression in basal/squamous type urothelial carcinoma cell line J82 cells
AR expression in J82 cells associated with reduced CLDN1 and CLDN4.
»
07/28/26
A multilevel intervention to improve adherence to prostate cancer active surveillance versus usual care: results from a pilot randomized controlled trial
multilevel intervention (MAP) is feasible to deploy and acceptable.
»
07/29/26
From motion to molecules: exercise-triggered large EVs suppress oncogenic signaling in lung adenocarcinoma cells – an in vitro pilot study
Exercise significantly increased plasma nanoparticle concentration.
»
07/29/26
Quantifying target antigen-dependent CAR T-cell performance against AML
Framework selects CAR T-cell expansion model that accounts for handling time and T-cell self-interference.
»
07/29/26
Early-onset colorectal cancer in Korea: clinical characteristics, treatment patterns, and survival outcomes in a K-CURE nationwide population-based study
Association between EOCRC and lower mortality stronger in MSI tumors.
»
07/30/26
PD-L1 expression across molecular driver subsets in non-small cell lung carcinoma: a 299-case real-world thoracic oncology cohort
PD-L1 high expression enriched among KRAS-mutant NSCLC.
»
07/30/26
A modular γδ TCR-T platform combining KRAS pMHC targeting with re-dosable mRNA engager redirection
LNP-M5 produced circulating TCE that redirected γδ A11v T cells and polyclonal bystander T cells
»
07/30/26
Trends in treatment and survival of stage IV non-squamous NSCLC from 2010 to 2022
Overall disease control rate 58% with median follow-up of 69.7 months.
»
07/31/26
Metabolic health at breast cancer diagnosis and two-year survival: a prospective cohort study in a public healthcare setting
Metabolic syndrome at diagnosis associated with lower overall survival.
»
07/31/26
< Prev
Next >